The primary aim of the study is to evaluate Spectris' efficacy in slowing the progression of Alzheimer’s against sham for mild to moderate patients. Credit: PeopleImages.com - Yuri A / Shutterstock. · ...
Cognito Therapeutics has reached its enrolment goal for the randomised, sham-controlled HOPE Study investigating the Spectris AD system’s efficacy and safety in treating Alzheimer's disease. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback